AutoVRse raises $2.4M from Singularity AMC and Lumikai to scale AI transformation for global Pharma and MedTech

AutoVRse, India’s fastest-growing industrial AI transformation platform, today announced a $2.4 million funding round, co-led by Singularity AMC’s Large Value Fund III and Early Opportunities Fund, and existing investor Lumikai, India’s leading interactive media, digital platforms and games VC.

AutoVRse deploys VR-based training and smart-glasses-enabled field guidance across pharmaceuticals, medical devices and healthcare. The company serves 500,000+ users at more than 50 enterprise customers across North America, Europe, the GCC and India, including five out of the Top-12 pharmaceutical companies globally (by market cap), one of the largest medical device manufacturers in the world, and several other major companies such as Intas, Abbott, Panasonic etc.

“AI in regulated industries – such as pharmaceutical and medical devices – must be 100% reliable and cite compliant documentation. Our years building VR training for pharma scientists and lab technicians taught us that the only way to do this is to capture verified expert knowledge, authored and validated by the customer’s own subject matter experts. We didn’t set out to build an AI company – we set out to train workers in VR, and in doing so we ended up building the knowledge layer that makes AI in regulated industries actually trustworthy. We’re grateful to Singularity AMC for backing this vision, and to Lumikai, who’ve believed in this bet for years.” said Ashwin Jaishanker, Co-Founder and CEO, AutoVRse.

The adoption of AI in operational workflows has been constrained by a fundamental challenge: the gap between what AI systems can process and what human experts know. For decades, industrial companies have relied on a small number of highly experienced workers to operate critical equipment, troubleshoot complex problems and maintain safety standards. As workforces grow and experienced employees retire, much of that institutional knowledge risks being lost. Decades of institutional knowledge – sterility protocols, equipment calibration sequences, cleanroom procedures, device-specific service techniques – remain tied to senior subject matter experts (SMEs), documented incompletely across fragmented SOPs, and dozens of disconnected vendor platforms. AutoVRse is solving for precisely this problem.

The company’s platform, VRseBuilder, works directly with an enterprise’s own domain experts — QA leads, cleanroom technicians, clinical applications specialists — to capture their procedural knowledge in a structured, machine-readable format. Every module is authored, reviewed and validated by these subject-matter experts (SME), ensuring that the AI layer is grounded in verified expert knowledge rather than generalised data. The result is an enterprise-grade “AI Brain”: a continuously enriched knowledge layer that converts siloed expertise into structured operational intelligence accessible to every technician, field service engineer and researcher — exactly when they need it, in context, and on the device they are using.

In regulated environments governed by Good Manufacturing Practices (GMP) and Quality System Regulations (QSR), training content cannot be approximated or auto generated without expert oversight. AutoVRse’s SME-led content creation model ensures that every procedure – whether  it is a sterile fill-finish operation in a pharmaceutical cleanroom, or a complex service intervention on a medical imaging device – is captured at the fidelity required to meet regulatory scrutiny, while simultaneously making that knowledge available for downstream AI applications such as real-time field guidance, digital twins and automated compliance documentation.  This is where AutoVRse’s approach differs fundamentally from conventional e-learning or even standard VR training tools.

“Most people think of AI in the context of consumer apps. AutoVRse is creating real impact with AI in pharma labs and hospitals, and that is what our investment thesis is built on. The company operates at the intersection of AI and India’s pharmaceutical revolution. We believe this is how the world will train and operate its industrial workforce over the next 10 years. AutoVRse sits at the edge of a massive, largely untapped market, and we believe the growth from here will be extraordinary.” said Yash Kela, Founder & Chief Investment Officer, Singularity AMC.

One marquee deployment illustrates the trajectory – a global medtech major began with a single proof-of-concept VR module for a service procedure on a flagship interventional device. Within a year, the engagement expanded to over 100 training modules covering the complete technical syllabus for that device and is now scaling across multiple additional product lines including MRI and ultrasound systems. The same customer is now using AutoVRse’s AI-powered smart-glasses product to provide real-time procedural guidance to 5,000+ field service engineers globally — effectively putting expert-level knowledge at their fingertips during live service interventions, rather than requiring them to recall classroom training or search through documentation.

In another example, a global pharmaceutical leader has already consolidated 72 different VR vendors onto AutoVRse’s AI-powered platform – a sign of how aggressively large healthcare companies are now standardising and gravitating towards a single, immersive, AI-native layer for workforce training, sales enablement and compliance.

The new capital raised will be used to fund compliance certifications — critical in regulated healthcare environments operating under GMP, QSR and ISO frameworks — and deepen integrations with customer infrastructure including learning management (LMS) and quality management (QMS) systems. The company also intends to scale its go-to-market in North America, where it is already running deployments with several Fortune 500 companies, and further expand its presence in Europe, the GCC and India.

“We’re thrilled to deepen our partnership with AutoVRse as they build out cutting-edge AI and VR infrastructure for Fortune 500 enterprises. With VRseBuilder, AutoVRse has demonstrated how immersion, participation and personalisation are finding consequential real-world applications across industrial training in warehouses, labs, plants and field operations of high-precision industries such as pharma, life sciences, manufacturing and petrochemicals, globally. We’re excited to back Ashwin, Adarsh and the team as they make immersive AI the operating layer for global industry.” said Aditya Deshpande, Principal, Lumikai.